NasdaqGS:AKTSBiotechs
Assessing Aktis Oncology (AKTS) Valuation After Recent Share Price Weakness And Negative Price To Book Ratio
Event-driven snapshot of Aktis Oncology
Aktis Oncology (AKTS) has drawn investor attention after recent trading, with the stock closing at US$18.98 and showing negative returns over the past week, month and year to date.
See our latest analysis for Aktis Oncology.
The recent 1 day share price return of a 3.01% decline, alongside 7 day and year to date share price returns of 13.65% and 15.27% declines, points to fading short term momentum after earlier optimism. Current moves likely reflect...